Simplification to dual-therapy containing lamivudine and darunavir/ritonavir or atazanavir/ritonavir in HIV-infected patients on virologically suppressive antiretroviral therapy

References

• Palella FJ, Delaney KM, Moorman AC, et al. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. N Engl J Med. 1998;388:853–860.
   Web of Science ®Google Scholar
• Palella FJ, Baker RK, Moorman AC, et al. Mortality in the highly active antiretroviral therapy era: changing causes of death and disease in the HIV outpatient study. J Acquir Immune Defic Syndr. 2006;43:27–34.
   PubMed Web of Science ®Google Scholar
• Margolis AM, Heverling H, Pham PA, et al. A review of the toxicity of HIV medications. J Med Toxicol. 2014;10:26–39.
   PubMedGoogle Scholar
• Hung KM, Chen PC, Hsieh HC, et al. Mitochondrial defects arise from nucleoside/nucleotide reverse transcriptase inhibitors in neurons: Potential contribution to HIV-associated neurocognitive disorders. Biochim Biophys Acta. 2017;1863:406–413.
   PubMed Web of Science ®Google Scholar
• Liang Q, Zeng J, Wu J, et al. Nucleoside reverse transcriptase inhibitors induced hepatocellular mitochondrial DNA lesions and compensatory enhancement of mitochondrial function and DNA repair. Int J Antimicrob Agents. 2017; Aug 23 [Epub ahead of print].
   Google Scholar
• Arribas JR, Girard PM, Paton N, et al. Efficacy of protease inhibitor monotherapy vs. triple therapy: meta-analysis of data from 2303 patients in 13 randomized trials. HIV Med. 2016;17:358–367.
   PubMed Web of Science ®Google Scholar
• Paton NI, Stöhr W, Arenas-Pinto A, et al. Protease inhibitor monotherapy for long-term management of HIV infection: a randomised, controlled, open-label, non-inferiority trial. Lancet HIV. 2015;2:e417–e426.
   PubMed Web of Science ®Google Scholar
• El Bouzidi K, Collier D, Nastouli E, et al. Virological efficacy of PI monotherapy for HIV-1 in clinical practice. J Antimicrob Chemother. 2016;71:3228–3234.
   PubMed Web of Science ®Google Scholar
• Girard PM, Antinori A, Arribas JR, et al. Week 96 efficacy and safety of darunavir/ritonavir monotherapy vs. darunavir/ritonavir with two nucleoside reverse transcriptase inhibitors in the PROTEA trial. HIV Med. 2017;18:5–12.
   PubMed Web of Science ®Google Scholar
• European AIDS. Clinical Society (EACS) Guidelines. Version 8.2; January 2017. Available at: http://www.eacsociety.org/files/guidelines_8.2-english.pdf.
   Google Scholar
• Baril JG, Angel JB, Gill MJ, et al. Dual therapy treatment strategies for the management of patients infected with HIV: a systematic review of current evidence in ARV-naive or ARV-experienced, virologically suppressed patients. PLoS One. 2016;11:e0148231.
   PubMed Web of Science ®Google Scholar
• Arribas JR, Girard PM, Landman R, et al. Dual treatment with lopinavir-ritonavir plus lamivudine versus triple treatment with lopinavir-ritonavir plus lamivudine or emtricitabine and a second nucleos(t)ide reverse transcriptase inhibitor for maintenance of HIV-1 viral suppression (OLE): a randomised, open-label, non-inferiority trial. Lancet Infect Dis. 2015;15:785–792.
   PubMed Web of Science ®Google Scholar
• Perez-Molina JA, Rubio R, Rivero A, et al. Simplification to dual therapy (atazanavir/ritonavir + lamivudine) versus standard triple therapy [atazanavir/ritonavir + two nucleos (t)ides] in virologically stable patients on antiretroviral therapy: 96 week results from an open-label, non-inferiority, randomized clinical trial (SALT study). J Antimicrob Chemother. 2017;72:246–253.
   PubMed Web of Science ®Google Scholar
• Di Giambenedetto S, Fabbiani M, Quiros Roldan E, et al. Treatment simplification to atazanavir/ritonavir + lamivudine versus maintenance of atazanavir/ritonavir + two NRTIs in virologically suppressed HIV-1-infected patients: 48 week results from a randomized trial (ATLAS-M). J Antimicrob Chemother. 2017;72:1163–1171.
   PubMed Web of Science ®Google Scholar
• Inker LA, Schmid CH, Tighiouart H, et al. Estimating glomerular filtration rate from serum creatinine and cystatin C. N Engl J Med. 2012;367:20–29.
   PubMed Web of Science ®Google Scholar
• Mondi A, Fabbiani M, Ciccarelli N, et al. Efficacy and safety of treatment simplification to atazanavir/ritonavir + lamivudine in HIV-infected patients with virological suppression: 144 week follow-up of the AtLaS pilot study. J Antimicrob Chemother. 2015;70:1843–1849.
   PubMed Web of Science ®Google Scholar
• Lombardi F, Belmonti S, Quiros-Roldan E, et al. Evolution of blood-associated HIV-1 DNA levels after 48 weeks of switching to atazanavir/ritonavir + lamivudine dual therapy versus continuing triple therapy in the randomized AtLaS-M trial. J Antimicrob Chemother. 2017;72:2055–2059.
   PubMed Web of Science ®Google Scholar
• Restelli U, Fabbiani M, Di Giambenedetto S, et al. Budget impact analysis of the simplification to atazanavir + ritonavir + lamivudine dual therapy of HIV-positive patients receiving atazanavir-based triple therapies in Italy starting from data of the Atlas-M trial. Ceor. 2017;9:173–179.
   Google Scholar
• Casado JL, Banon S, Moreno A, et al. Lamivudine plus darunavir boosted with ritonavir as simplification dual regimen in HIV-infected patients. J Int AIDS Soc. 2014;17:19801
   PubMed Web of Science ®Google Scholar
• Borghetti A, Mondi A, Piccoli B, et al. Switching to lamivudine plus darunavir/r dual therapy in a cohort of treatment-experienced HIV-positive patients: the experience of an Italian centre. J Int AIDS Soc. 2014;17:19817.
   PubMed Web of Science ®Google Scholar
• Fabbiani M, Di Giambenedetto S, Poli A, et al. Simplification to a dual regimen with darunavir/ritonavir plus lamivudine or emtricitabine in virologically-suppressed HIV-infected patients. J Infect. 2016;73:619–623.
   PubMed Web of Science ®Google Scholar
• Ciaffi L, Koulla-Shiro S, Sawadogo AB, et al. Boosted protease inhibitor monotherapy versus boosted protease inhibitor plus lamivudine dual therapy as second-line maintenance treatment for HIV-1-infected patients in sub-Saharan Africa (ANRS12 286/MOBIDIP): a multicentre, randomized, parallel, open-label, superiority trial. Lancet HIV. 2017;4:e384–e392.
   PubMed Web of Science ®Google Scholar
• Martin A, Bloch M, Amin J, et al. Simplification of antiretroviral therapy with tenofovir-emtricitabine or abacavir-Lamivudine: a randomized, 96-week trial. Clin Infect Dis. 2009;49:1591–1601.
   PubMed Web of Science ®Google Scholar
• Dejesus E, Young B, Morales-Ramirez JO, et al. Simplification of antiretroviral therapy to a single-tablet regimen consisting of efavirenz, emtricitabine, and tenofovir disoproxil fumarate versus unmodified antiretroviral therapy in virologically suppressed HIV-1-infected patients. J Acquir Immune Defic Syndr. 2009;51:163–174.
   PubMed Web of Science ®Google Scholar
• Martinez E, Larrousse M, Libre JM, et al. Substitution of raltegravir for ritonavir-boosted protease inhibitors in HIV-infected patients: the SPIRAL study. AIDS. 2010;24:1697–1707.
   PubMed Web of Science ®Google Scholar
• Eriksen J, Albert J, Blaxhult A, et al. Antiretroviral treatment for HIV infection: Swedish recommendations 2016. Infect Dis (Lond). 2017;49:1–34.
   PubMed Web of Science ®Google Scholar